University of Worcester Worcester Research and Publications
 
  USER PANEL:
  ABOUT THE COLLECTION:
  CONTACT DETAILS:

Treatment of Cancer‐Associated Venous Thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomisation of the SELECT‐D Trial. (SELECT‐D: 12m)

Marshall, A. ORCID: https://orcid.org/0000-0002-6610-5812, Levine, M., Hill, C., Hale, D., Thirlwall, J., Wilkie, Veronica ORCID: https://orcid.org/0000-0003-3584-0942, French, K., Kakkar, A., Lokare, A., Maraveyas, A. ORCID: https://orcid.org/0000-0003-4176-5176, Chapman, O., Arif, A., Petrou, S., Maredza, M., Hobbs, F.D.R., Dunn, J. and Young, A. M. (2020) Treatment of Cancer‐Associated Venous Thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomisation of the SELECT‐D Trial. (SELECT‐D: 12m). Journal of Thrombosis and Haemostasis, 18 (4). pp. 905-915. ISSN 1538-7836

[img] Text
AAM-with-cover-9144-Marshall-etal-Wilkie-treatment-of-cancer-associated-venous-thromboembolism.pdf - Accepted Version
Restricted to Repository staff only until 29 January 2021.

Download (12MB) | Request a copy

Abstract

Background The SELECT‐D trial demonstrated reduction in recurrent venous thromboembolism (VTE) but increased bleeding with rivaroxaban compared to dalteparin for treatment of acute VTE in cancer patients, at 6 months. Uncertainty remains around optimal duration of anticoagulation. Objectives To assess VTE recurrence and bleeding, with anticoagulation or not, beyond 6 months Patients/Methods In SELECT‐D, after 6 months of trial treatment for VTE, patients with active cancer and residual deep vein thrombosis (RDVT) or index pulmonary embolism (PE) were eligible for randomisation to a further 6 months of rivaroxaban or placebo. Patients with no RDVT stopped anticoagulation. Primary outcome was VTE recurrence at 12 months. The second randomisation closed prematurely due to low recruitment when 92 of the planned 300 patients were recruited. Results 92 of 136 eligible patients were randomised to rivaroxaban or placebo. The cumulative VTE recurrence after 6 months from the second randomisation, was 14% with placebo and 4% with rivaroxaban (Hazard Ratio 0.32; 95% CI 0.06‐1.58). The major and clinically‐relevant non‐major bleeding rates were 0% and 0% with placebo; and 5% (95% CI 1‐18%) and 4% (95% CI 1‐17%) with rivaroxaban. In an exploratory analysis, 7 (15.2 %) of 46 placebo patients with RDVT or an index PE experienced recurrent VTE compared to none in the 35 patients in the RDVT‐negative cohort (P=0.03). Conclusion The SELECT‐D trial was underpowered to detect a statistically significant reduction in recurrent VTE with extended anticoagulation. The absence of RDVT and/or index PE, defined a population at low risk of recurrence.

Item Type: Article
Additional Information:

Staff and students at the University of Worcester can access the full-text of the online published article via the official URL. External users should check availability with their local library or Interlibrary Requests Service.

Uncontrolled Keywords: cancer-associated thrombosis, treatment duration, direct oral anticoagulant, venomous thromboembolism recurrence, bleeding
Divisions: College of Health, Life and Environmental Sciences > School of Allied Health and Community
Related URLs:
SWORD Depositor: Prof. Pub Router
Depositing User: Veronica Wilkie
Date Deposited: 07 Feb 2020 16:51
Last Modified: 09 Apr 2020 08:59
URI: https://eprints.worc.ac.uk/id/eprint/9144

Actions (login required)

View Item View Item
 
     
Worcester Research and Publications is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.